Disease · HP_0004326
Cachexia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Cachexia. Diseases, record HP_0004326. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0004326
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Cachexia
- Open Targets ID
- HP_0004326
- Other names
- Wasting syndrome
- Highest stage of its drugs
- Approval, for 2 of its 37 drugs, from DailyMed
Source Open Targets
Drugs37
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| MEGESTROL ACETATE | CHEMBL1201139 | Small molecule | Approval | DailyMed | 7 | 6 | 6 | Drugs and targets |
| SOMATROPIN | CHEMBL1201621 | Protein | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| ANAMORELIN | CHEMBL2110579 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 3 | 3 | Drugs and targets |
| MELATONIN | CHEMBL45 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANAMORELIN HYDROCHLORIDE | CHEMBL2103794 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| PONSEGROMAB | CHEMBL4650502 | Antibody | Phase 2/3 | ClinicalTrials.gov | 3 | 2 | 2 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| IRINOTECAN | CHEMBL481 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| OXALIPLATIN | CHEMBL414804 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
1 to 10 of 37
See all 37 drugsTargets67
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GHSR | Growth hormone secretagogue receptor type 1 | 4 | Ghrelin receptor agonist | Phase 3 | https://conductscience.org/library/genes/2693 | Drugs and targets |
| ACVR2B | Activin receptor type-2B | 1 | Activin receptor type-2B antagonist | Phase 2 | https://conductscience.org/library/genes/93 | Drugs and targets |
| ADORA1 | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2 | https://conductscience.org/library/genes/134 | Drugs and targets |
| ADORA2A | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2 | https://conductscience.org/library/genes/136 | Drugs and targets |
| ADORA3 | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2 | https://conductscience.org/library/genes/140 | Drugs and targets |
| AR | Androgen receptor | 1 | Androgen Receptor modulator | Preclinical | https://conductscience.org/library/genes/367 | Drugs and targets |
| CCDC6 | Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET | 1 | Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor | Early phase 1 | https://conductscience.org/library/genes/8030 | Drugs and targets |
| CRBN | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 1/2 | https://conductscience.org/library/genes/51185 | Drugs and targets |
| CUL4A | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 1/2 | https://conductscience.org/library/genes/8451 | Drugs and targets |
1 to 10 of 67
See all 67 targetsTrials34
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01395914 | Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3) | Phase 3 | 513 | 2017-07-11 | Cachexia, Non-Small Cell Lung Cancer | ANAMORELIN | Its record names the disease | ClinicalTrials.gov |
| NCT03743051 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1 | Phase 3 | 318 | 2024-06-26 | Cachexia; Cancer, Non Small Cell Lung Cancer | ANAMORELIN | Its record names the disease | ClinicalTrials.gov |
| NCT03743064 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2 | Phase 3 | 318 | 2024-06-26 | Cachexia; Cancer, Non Small Cell Lung Cancer | ANAMORELIN | Its record names the disease | ClinicalTrials.gov |
| NCT00513357 | Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients | Phase 3 | 82 | 2012-09-14 | Gastrointestinal Cancer, Lung Cancer | MELATONIN | Its record names the disease | ClinicalTrials.gov |
| NCT01433263 | Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas | Phase 2 | 57 | 2015-05-13 | Cachexia | BIMAGRUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01614990 | Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia | Phase 2 | 15 | 2024-03-19 | Cancer Cachexia | MACIMORELIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04299048 | Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. | Phase 1 | 11 | 2023-12-14 | Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer | PONSEGROMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01505764 | The Role of Ghrelin in Cancer Cachexia | Phase 2 | 10 | 2017-02-24 | Cancer Cachexia | ANAMORELIN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02479451 | Helping Olfaction and Nutrition On Renal Replacement | Phase 2 | 7 | 2024-01-09 | End Stage Renal Disease, Olfactory Disorders | THEOPHYLLINE | Its record names the disease | ClinicalTrials.gov |
| NCT00558558 | Haelan and Nutrition in Cancer Patients | Phase 2 | 6 | 2011-10-12 | Anorexia, Weight Loss, Cachexia | FLURANDRENOLIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 34
See all 34 trialsComparisons in its trials9
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Anamorelin HCl vs Placebo: serious adverse events | 44 of 343 | 21 of 167 | 510 | NCT01395914 | Trial comparisons |
| 100 mg Anamorelin HCl vs Placebo: deaths from any cause | 27 of 159 | 26 of 159 | 318 | NCT03743051 | Trial comparisons |
| 100 mg Anamorelin HCl vs Placebo: serious adverse events | 43 of 159 | 39 of 159 | 318 | NCT03743051 | Trial comparisons |
| 100 mg Anamorelin HCl vs Placebo: deaths from any cause | 25 of 154 | 28 of 164 | 318 | NCT03743064 | Trial comparisons |
| 100 mg Anamorelin HCl vs Placebo: serious adverse events | 44 of 154 | 46 of 164 | 318 | NCT03743064 | Trial comparisons |
| Melatonin vs Placebo: serious adverse events | 2 of 38 | 2 of 35 | 73 | NCT00513357 | Trial comparisons |
| Macimorelin vs Placebo: deaths from any cause | 0 of 10 | 0 of 5 | 15 | NCT01614990 | Trial comparisons |
| Macimorelin vs Placebo: serious adverse events | 1 of 10 | 0 of 5 | 15 | NCT01614990 | Trial comparisons |
| Arm 1 (Anamorelin HCl) vs Arm 2 (Placebo): serious adverse events | 3 of 6 | 1 of 4 | 10 | NCT01505764 | Trial comparisons |
Papers from its trials12
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0004326
GET https://conductscience.org/api/diseases/v1/HP_0004326/drugs?page=2